A Prospective, Single-Center, Investigator Initiated Clinical Study to Evaluate theEffectiveness and Safety of Thymosin Î±-1 (TÎ±1) in severe COVID-19 patients

Dr Rahul Pandit0 个研究点目标入组 15 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Male females of greater than or equal to 18 years of age at the time of consent
•2.Patient who can and willing to provide written Informed Consent
•3.Severe Acute Respiratory Syndrome Coronavirus SARS CoV 2 infection confirmed by polymerase chain reaction PCR test any other confirmatory tests
•4.If the patient presents any one of the following features
•respiratory distress with a respiratory rate greater than equal toâ??30 breath per min
•SpO2 oxygen saturation less than or equal toâ??90 percentage on room air
•PaO2 arterial blood oxygen partial pressure FiO2 Fraction of Inspired Oxygen less than or equal toâ??200 mmHg 1 mmHgâ??0.133 kPa
•Patient presents respiratory failure and requires mechanical ventilation support
•5.Patient patients LAR understands and is willing to participate in the clinical study and can comply with clinical trial protocol requirements.

•1 Patient who has participated in any other clinical trial of an experimental treatment for COVID-19
•2 Patient with presence of any pre-existing illness that, in the opinion of the investigator, would place the patient at an unreasonably increased risk through participation in this study.
•3 Patient who has participated in another trial with an investigational drug within 1 month prior to this trial.
•4 Patients who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol

发起方

Dr Rahul Pandit